SATB2 Induces Malignant Transformation and Cancer Stem Cell Characteristics, and Inhibition of Its Expression Reverses Drug Resistance in Mesothelioma

Our plain-English summary of SATB2 Induces Malignant Transformation and Cancer Stem Cell Characteristics, and Inhibition of Its Expression Reverses Drug Resistance in Mesothelioma, by C. Brown, S. Srivastava, R. Srivastava, et al (Cells, 2026).

The study

• Authors: C. Brown, S. Srivastava, R. Srivastava, R. Srivastava, J. Morvant, A. Shrivastava, R.K. Srivastava
• Journal: Cells
• Published: 2026;15(3)
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

SATB2 (special AT-rich binding protein 2) functions as a chromatin-associated epigenetic regulator that modulates gene expression, in part by serving as a transcriptional cofactor. This study assessed whether SATB2 overexpression is sufficient to promote in vitro transformation of human mesothelial cells and whether SATB2 suppression in mesothelioma cancer stem cell (CSC)-enriched populations is associated with altered chemoresistance. SATB2 expression was high in human malignant pleural mesothelioma (MPM) cell lines but absent in Met5A mesothelial cells. Ectopic SATB2 expression in Met5A cells was associated with acquisition of malignant and stem cell-like phenotypes, including increased expression of stem cell markers and pluripotency-associated factors, as well as anchorage-independent growth in soft agar and spheroid formation in suspension culture. In contrast, Met5A cells transduced with an empty vector did not form colonies or mesospheres. SATB2 overexpression in Met5A cells was also associated with increased motility, migration, and invasion, accompanied by induction of epithelial-mesenchymal transition (EMT)-related transcription factors relative to empty vector controls. Conversely, shRNA-mediated SATB2 knockdown in an MPM cell line attenuated proliferation, EMT-associated features, and CSC-like characteristics. Chromatin immunoprecipitation assays identified SATB2 occupancy at promoter regions of Bcl2, XIAP, KLF4, c-Myc, NANOG, and SOX2, consistent with a role in transcriptional regulation of genes linked to transformation, pluripotency, cell survival, proliferation, and EMT. In CSC-enriched cells, SATB2 inhibition was associated with increased sensitivity to cisplatin and pemetrexed, concomitant with reduced OCT4 and SOX2 expression. Collectively, these findings support SATB2 as a candidate therapeutic target in MPM and suggest that SATB2 suppression may enhance chemotherapy response when combined with standard agents.

In plain English

This was an in vitro laboratory study of SATB2 in human mesothelial and malignant pleural mesothelioma (MPM) cells. The authors reported that SATB2 was not expressed in the normal mesothelial line Met5A but was expressed in the mesothelioma lines H2714, H2452 and H2595. In commercially purchased tissue sections, SATB2 staining (H-Score, n = 40) was higher in mesothelioma than normal mesothelial tissue, with an area under the ROC curve of 0.9939 ± 0.0005 SE (95% CI = 0.985 to 1, p < 0.0001). Using TCGA data, the authors reported higher SATB2 in male (n = 71) than female (n = 16) patients and poorer survival with high (n = 22) versus low/medium (n = 63) SATB2. Forcing SATB2 expression in Met5A cells was accompanied by spheroid formation, stem-cell and pluripotency markers, and EMT features. In H2452 cultures, shRNA knockdown of SATB2 reduced growth, colony formation, motility, migration and invasion; in cancer stem cell-enriched populations derived from H2452, it reduced mesosphere formation and increased sensitivity to cisplatin (20 µM) and pemetrexed (1 µM).

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: in vitro laboratory study of human cell lines, with tissue-array immunohistochemistry and analysis of public TCGA data
• Who was studied: Human mesothelioma cell lines H2714, H2452 and H2595 and the mesothelial cell line Met5A (ATCC); purchased normal mesothelial and mesothelioma tissue arrays (n = 40); TCGA data from 71 male and 16 female mesothelioma patients
• Exposure: Lentiviral overexpression of SATB2 cDNA in Met5A cells and shRNA knockdown of SATB2 in H2452 mesothelioma cells and in cancer stem cells isolated from H2452; drug treatment with cisplatin (20 µM) or pemetrexed (1 µM) for 3 weeks
• Main results:
  • SATB2 mRNA was absent in Met5A mesothelial cells but high in the mesothelioma cell lines
  • By immunocytochemistry, the lowest SATB2 expression was in H2714 and the highest in H2452
  • SATB2 staining distinguished mesothelioma from normal mesothelial tissue with an area under the ROC curve of 0.9939 ± 0.0005 SE (95% CI = 0.985 to 1, p < 0.0001)
  • In TCGA data, higher SATB2 expression (n = 22) was associated with poorer survival than low/medium expression (n = 63) in MPM patients
  • Met5A cells overexpressing SATB2 formed spheroids and showed increased stem cell markers and pluripotency factors, whereas empty-vector Met5A cells formed no mesospheres
  • SATB2 overexpression in Met5A cells reduced E-cadherin and increased N-cadherin and raised Slug, Snail and Zeb1, compared with empty vector controls
  • SATB2 shRNA reduced colony formation in H2452 cells compared with scrambled controls
  • The authors reported that SATB2 knockdown suppressed proliferation in the mesothelioma cells
  • XIAP mRNA and protein were lower in the H2452/SATB2 shRNA group than in the H2452/scrambled group
  • SATB2 shRNA in H2452 cells lowered motility, migration and invasion compared with scrambled controls
  • In CSCs isolated from H2452, SATB2 shRNA reduced cell viability in primary, secondary and tertiary mesospheres
  • ChIP in H2452 cancer stem cells showed SATB2 binding at promoters of Bcl2, XIAP, KLF4, cMyc, Nanog and Sox2
  • In CSCs isolated from H2452, cisplatin and pemetrexed alone did not affect mesosphere formation, but SATB2 shRNA inhibited mesosphere formation and sensitized the cells to both drugs
• The authors' conclusion: The authors concluded that SATB2 can induce oncogenic transformation of normal mesothelial cells into cancer stem-like cells and that SATB2 may be considered a therapeutic target in MPM, with inhibition combined with chemotherapy as a possible treatment option
• Limitations the authors state:
  • All experiments were done in vitro; in vivo work would be needed
  • Only one normal mesothelial cell line was used for overexpression
  • Met5A was immortalized with SV40 large T-antigen, which may have influenced results
  • Therapeutic potential would require development of a small-molecule SATB2 inhibitor

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma.

Medical terms in this study, explained in our Lexicon: Malignant Transformation, STEM, Mesothelioma, Mesothelial Cells, Pleural Mesothelioma, Cisplatin, Pemetrexed (Alimta), Chemotherapy.

Related studies

• Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed — L. Cortes-Dericks, G.L. Carboni, et al. (2010)
• TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation — A. Matsushita, T. Sato, et al. (2019)
• Long-term exposure of mesothelial cells to SV40 and asbestos leads to malignant transformation and chemotherapy resistance — A.L. Cleaver, K. Bhamidipaty, et al. (2014)
• Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis — C.W. Menges, Y. Kadariya, et al. (2014)
• Multipotent cancer stem cells derived from human malignant peritoneal mesothelioma promote tumorigenesis — S. Varghese, R. Whipple, et al. (2012)
• Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells — A. Buqué, U. Aresti, et al. (2013)

Browse more research in Cells, or return to medical research.